BlackRock, Inc. 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-17 7:44 pm Purchase |
2025-06-30 | 13G | Aclaris Therapeutics, Inc. ACRS |
BlackRock Inc. BLK |
5,471,711 5.100% |
3,439,247 (+169.22%) |
Filing |
| 2024-07-08 4:32 pm Sale |
2024-06-30 | 13G | Aclaris Therapeutics, Inc. ACRS |
BlackRock Inc. BLK |
2,032,464 2.900% |
-3,873,408 (-65.59%) |
Filing |
| 2024-01-25 4:59 pm Purchase |
2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
BlackRock Inc. BLK |
5,905,872 8.300% |
818,437 (+16.09%) |
Filing |
| 2023-01-31 1:58 pm Purchase |
2022-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
BlackRock Inc. BLK |
5,087,435 7.600% |
1,008,560 (+24.73%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
BlackRock Inc. BLK |
4,078,875 6.700% |
3,031,059 (+289.27%) |
Filing |